Other languages Personalis, Inc.

Equities

PSNL

US71535D1063

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
1.265 ^USD	+1.20%		-1.94%	-39.76%

26/03	Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	CI
29/02	Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	26/03
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	29/02
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Personalis to Offer ClearNote's Epigenomic Platform in Partnership	30/01
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	30/01
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay	16/01
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	05/01
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test	29/11
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing	29/11
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	17/11
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	17/11
Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023	08/11
Personalis, Inc. Revises Earnings Guidance for the Full Year 2023	08/11
Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer	26/23/26
Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study	21/23/21
Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance	19/23/19
Personalis, Inc. Receives New Task Order Under Its Contract with the U.S. Department of Veterans Affair	29/23/29
Personalis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Personalis, Inc.

Equities

PSNL

US71535D1063

Other languages

Filters